Protocol for a controlled human infection with genetically modified expressing the meningococcal vaccine antigen NadA: a potent new technique for experimental medicine.

Introduction: is a commensal organism found in the human nasopharynx and is closely related to the pathogen (meningococcus). Carriage of is associated with reduced meningococcal carriage and disease. We summarise an ethically approved protocol for an experimental human challenge study using a genetically modified strain of that expresses the meningococcal antigen NadA.

Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine.

With the successful development of meningococcal vaccines against other serogroups, disease caused by Neisseria meningitidis serogroup B now accounts for a disproportionate frequency compared with other serogroups, particularly in the US and Europe. Infants and adolescents bear the highest incidence of disease, which typically manifests as meningitis and septicemia. This vaccine profile article examines a bivalent factor H binding protein (fHbp; also known as LP2086) vaccine that has now been approved by the US FDA for use in 10- to 25-year olds.